TCP-25 / Xinnate - LARVOL DELTA

Results of a non-randomized, open-label phase I study evaluating the novel Immunomodulatory peptide TCP-25 for treatment of dystrophic epidermolysis bullosa. (PubMed, Orphanet J Rare Dis) - No abstract available

Journal • P1 data

Functionalized peptide hydrogels: enabling dynamic stage-adaptive modulation for wound healing. (PubMed, Front Cell Dev Biol) - "For instance, antimicrobial peptides (e.g., EPL, LL37, TCP-25) not only eradicate pathogens but also modulate macrophage polarization to mitigate excessive inflammation...With inherent self-healing, injectability, and microenvironmental responsiveness (e.g., to pH, enzymes, or ROS), these hydrogels adapt to dynamic wound conditions, offering synergistic therapeutic outcomes. Future directions include designing multi-stimuli-responsive systems, personalized peptide sequences, and advanced delivery platforms (e.g., 3D-printed scaffolds, cell/exosome-loaded hydrogels) to advance clinical translation in precision wound management and regenerative medicine."

Journal • Review • Inflammation • CXCL12

TCP-25 Reduces Pro-Inflammatory Cytokine Secretion in Human Dermal Fibroblasts Stimulated with Lipopolysaccharide (ESDR 2025) - "The capacity of TCP-25 to reduce this response demonstrates a novel anti-inflammatory effect of TCP-25. Further in vivo studies are warranted to investigate the relevance of these findings in the context of bacteria and wound healing."

CXCL8 • IFNG • IL10 • IL12A • IL13 • IL1B • IL2 • IL4 • IL6 • TNFA

Topical TCP-25 Modulates MMP-2 Levels During Epidermal Wound Healing (ESDR 2025) - P1 | "In conclusion, topical TCP-25 treatment reduced MMP-2 levels during human epidermal wound healing without complete inhibition, indicating a modulatory effect. Further studies are warranted in more complex wounds where MMP dysregulation is implicated."

MMP2 • MMP9

Topical treatment with TCP-25, a novel immunomodulatory peptide, in epidermolysis bullosa: a phase I study (ESDR 2025) - "In summary, these results established TCP-25 gel as safe and well-tolerated. The observed wound-healing benefits bring out TCP-25's potential as a promising new treatment for DEB."

Immunomodulating • P1 data • Dermatology • Non-melanoma Skin Cancer • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • CD14

A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study (clinicaltrials.gov) - P2 | N=26 | Not yet recruiting | Sponsor: Xinnate AB | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Jun 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date

A murine pressure ulcer model for evaluating persistence and treatment of Staphylococcus aureus infection. (PubMed, Front Med (Lausanne)) - "To validate the model's utility, we evaluated the antimicrobial efficacy of TCP-25, a synthetic host defense peptide, delivered in a topical gel formulation. Our findings highlight the potential of this model for investigating wound infection mechanisms, bacterial persistence, and therapeutic interventions. This innovative approach represents a significant advancement in pressure ulcer research, offering new opportunities for developing effective treatment strategies and improving patient outcomes."

Journal • Preclinical • Infectious Disease